Blue Armor 1A
- Eligible for a tax reduction
Arnaud Collard
CEO
Veterinarian specialized in aquaculture, Arnaud brings over 8 years of experience in fish health, combining field expertise with business acumen. He previously held key positions at MSD Animal Health and Ictyopharma, where he led vaccination strategies, biosecurity protocols, and epidemic response in salmonid farms across Europe and Africa. With a dual background in veterinary science and international business (MBA), he has successfully managed complex, multi-stakeholder projects and developed deep knowledge of the aquaculture sector’s technical and commercial ecosystems. As CEO of Blue Armor, he drives the company’s strategic vision and market deployment with a clear mission: to accelerate sustainable innovation in fish health.
Ronan Rouxel
Co-founder
PhD in Virology and Immunology, Ronan Rouxel is an internationally recognized vaccinologist with over 15 years of experience in the development, registration, and management of viral vaccines—both in human and aquatic animal health. Former Director of R&D and Site Manager at MSD Animal Health Norway, he has overseen the full development cycle of fish vaccines, managed teams of over 20 scientists, and successfully led regulatory interactions with EMA and USDA. Ronan is an expert in molecular biology, RNA platforms, and cold-water pathogens. At Blue Armor, he leads innovation and product development, bringing deep scientific leadership and regulatory insight to the company’s RNA vaccine platform
Hugues Wallemacq
Board member
Hugues Wallemacq is an accomplished entrepreneur and biotech strategist with a strong background in diagnostics, life sciences, and veterinary health. He has co-founded and advised several high-impact startups and has held leadership roles in business development and R&D strategy. With deep expertise in translational innovation and market access, Hugues brings valuable guidance to Blue Armor’s strategic positioning, investor relations, and scientific roadmap. His experience in both startup ecosystems and international biotech firms strengthens the company’s capacity to scale and attract key partners.
Emiel Hendriks
Board member
Emiel Hendriks is a seasoned expert in veterinary regulatory affairs, with over two decades of experience in navigating European and global frameworks for animal health products. He has held senior roles at leading pharmaceutical companies and now serves as a consultant supporting the development, registration, and lifecycle management of veterinary vaccines and therapeutics. His in-depth knowledge of regulatory compliance and dossier submission is instrumental in accelerating Blue Armor’s path to market for RNA-based vaccines.
Maarten de Gussem
Board member
Maarten De Gussem is a veterinarian and a specialist in veterinary diagnostics, vaccine production, and animal health technologies. Founder of Vetworks and affiliated with Poulpharm, he has extensive experience in industrial-scale health solutions for livestock, particularly poultry. His expertise spans GMP-compliant manufacturing, regulatory quality systems, and international product deployment. At Blue Armor, he advises on manufacturing strategy and process design to ensure efficient scale-up and compliance with veterinary standards.
Alain Vanderplasschen
Board member
Alain Vanderplasschen is Full Professor of Virology and Vaccinology at the University of Liège, with a globally recognized academic and research career in immunology and fish health. He leads pioneering research on viral pathogenesis and vaccine platforms, particularly for aquatic species. With over two decades of scientific contributions, multiple patents, and leadership in EU-funded collaborative projects, he brings high-level scientific oversight to Blue Armor’s vaccine development pipeline. His guidance ensures strong preclinical design, challenge model validation, and alignment with academic and regulatory standards.
TAX SHELTER 45%
Investments in this company benefit from a 45% personal income tax reduction. Read more…Raise summary
| Crowd investments | €120,500 |
| Committed by others | €0 |
| Amount raised | €120,500 |
| Minimum round | €100,000 |
| Maximum round | €1,000,000 |
| Shares in the company (total round) | 46.12% |
| Pre-money valuation | €1,168,278 |
| Post-money valuation min. | €1,268,278 |
| Post-money valuation max. | €2,168,278 |